Varian Medical Systems — Investor Presentation (September 2019)
58 slides from Varian Medical Systems's investor presentation, Sep 16, 2019

Slide 1: Transforming Cancer Care
varian Transforming Cancer Care Investor Relations inyestors@varian.com

Slide 2: Agenda
Agenda @ Introduction J, Michael Bruft , Finance and Investor Relations © Company Overview & Strategy © innovation Highlights © Q&A and Closing Remarks Dow Wilson Officer Chris Toth President, Oncology Systems: ‘Andrew Shogan SVP,CTSI Corey Zankowski ‘SVP, Oncology Software Solutions. Kolleen Kenned

Slide 3: Forward-Looking Statements
This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking Statements Except for historical contains within the meaning of the Private Securities Ligation Reform Act of 1995, Eecinres cocci many eee hetairg gout avers hace tee conor mcb

Slide 4: Company Overview & Strategy
varian Company Overview & Strategy Dow Wilson President and Chief Executive Officer

Slide 5: Global leader in RO
Global leader in RO Varian: 1948 to 2010 Electronic *Documentation roterrals ‘a Staging Registration «Tumor board “Scheduling «Genomics b Patient Intake 8 PoRnWesto Use Ouer Care Team Coordination 4 9 es Surgical Gnidlogy Oncology Sncalcay Information B’xnalytes Practice Management als machine Corni

Slide 6: R&D investments delivering world class integrated portfolio
R&D investments delivering world class integrated portfolio Voice of the customer informs investment decisions BRAVOS" is) HALCYON Oo pyBEAM Sheatesy — (Q) HyperArc | = =e win RapidPlan NeaieRE 2 FleshForward™ 3% : E ATUSBEAM 27% 3 evo FY FY2 FY]. FMA FY FYB G3 FYI YTD varian For nveston Use ony

Slide 7: Varian's comprehensive cancer care portfolio
Varian’s comprehensive cancer care portfolio i | Gi: Walon” Tan valor Cancer Treatment eam Pecan 30 -26 & es: ° h g Hardware & Software Services wv varian

Slide 8: Key acquisitions
Key acquisitions Expanding into broader cancer care market Prior to Varex spin-off, acquisitions were focused on growing core radiation therapy business hhumedio 1 Acquisition to expand market Acquisition to support core radiotherapy business ——E ee Teen Someone Eee Se pect, ee ee O e ° ; A way vari

Slide 9: Varian today — a snapshot
Varian today — a snapshot Touching more than 4+ million patients per year* RT LEADER: +12% Revenues and +11% Orders Oncology Systems TTM ‘growth with largest global installed base SOFTWARE: +16% TTM Software revenues growth SERVICES: NPS? of 78 with +7% TTM Services revenues growth TSI: Powering new

Slide 10: Largest linear accelerator installed base
Largest linear accelerator installed base Net installed base trend Drivers of Installed Base Growth ap ASE foe Innovation in integrated hardware, software and services portfolio Investing in field capacity focused on emerging markets, upgrades and software Fyi2FYia FYié FYIB FYIG FYI7 FYB Net instal

Slide 11: Varian revenue mix and operating earnings recent trends
Varian revenue mix and operating earnings recent trends bc AT <iieonen ee 600 z 52% . m , 3 54% 55% we fe 7 He al 3 Boy 180% 2 4 : é 3 ses0 2 2 10% g 2 s400 ay 3 48% 48% 45% é 2 g 2 5 sso g § a so00 : Pir rie carvievTo fvi7 fie TmaaRYB ‘= international as % of Total Revenues sm Operating Eamings ‘No

Slide 12: Varian revenue mix changing
Varian revenue mix changing Oncology HW and SW Licenses Oncology orders remains a relevant leading indicator for future hardware and software revenue Recurring-type revenues (e.g. HW services and SW service agreements) increasing as percent of total revenues Emerging businesses and technologies reve

Slide 13: Global leader in RO
Global leader in RO Varian: 1948 to 2010 Electronic *Documentation roterrals ‘a Staging Registration «Tumor board “Scheduling «Genomics b Patient Intake 3) Pon mvestor user Care Team Coordination 4 9 es Surgical Gnidlogy Oncology Sncalcay Information B’xnalytes Practice Management als machine Cornin

Slide 14: Intelligent Cancer Care: Varian today
. Care Team Coordination i eee fe Intelligent Cancer Care 7 COnGIauSty aon! Varian: Today i cf technology ecosystem tscptnary "umor board emer, if a ton Mn ie ; & ° RT ‘Simulation — Treatment rane lag, Seite, ‘Electtonlc «Dewan “apes. “Surwvoratip a eo nee, aurtene . = oe eg == aeeee “Radiomies Ieto

Slide 15: Oncology Systems
varian Oncology Systems Chris Toth President, Oncology Systems

Slide 16: ASTRO 2019 highlights
ASTRO 2019 highlights varian

Slide 17: The Gap in Care is Widening
The Gap in Care is Widening Demographics driving needs & market growth Cancer burden Skis 9 AeREREEREE eREREEEERE Tithe deeeeeeeee setehieee teheeeete =) Current RT market growing mid-single digits ing global demand

Slide 18: Eclipse, ARIA Oncology
Eclipse™ , ARIAS 360 Oncology™ vera ae ual Innovative solutions addressing market demand Vid — SRS/SBRT & new standards of Brain metastases = most Leaming curve reduced and care driving replacement cycle common recurrence, powering quality increased with machine with TrueBeam® & Haleyon™ HyperAro™ d

Slide 19: World's 1st AI powered adaptive therapy system
World’s 1* Al powered adaptive therapy system varian

Slide 20: Realizing Personalized Adaptive Radiation Therapy
Realizing Personalized Adaptive Radiation Therapy The culmination of a multi-decade pursuit of innovation IMRT. dose ® conformity & felty = BUT, patients’ anatomy & \ ——o tumors change Lay 2005-2010 IGRT. target precision Positioning GOAL: Maximize dose to tumor, minimize to healthy tissue varian

Slide 21: Realizing Personalized Adaptive Radiation Therapy
Realizing Personalized Adaptive Radiation Therapy The culmination of a multi-decade pursuit of innovation 1998-2000 'N IMRT: dose conformity & fidelity 2005-2010 IGRT: target precision positioning Today and beyond Ethos: characteristic spirit of a culture, era, or community Personalizing treatment d

Slide 22: Revolutionary workflow & integration
Revolutionary workflow & integration ov: Mark Ses es A» (k) Pending st Patient treated : 5 Booth Demo: Monday Sep. 16 @ 4:30pm - 5:00pm CT Varian
![Slide 23: 2) so) @ a ) i] if](https://6ix-events-pro.s3.amazonaws.com/decks/p/bnid4bw5/23.webp)
Slide 23: 2) so) @ a ) i] if
2) so) @ a ) i] if

Slide 24: aasBotea &
aasBotea & ‘oot eters an Sac pe

Slide 25: Ethos Therapy
Ethos Therapy™ World’s 1% Al powered adaptive therapy solution 1. Al-driven, streamlined workflows 2. Access to CT, MR, PET images 3. Patient Centric, 100cm bore/quiet delivery Enabling adaptive treatment delivery in the typical 15-minute timeslot! varian

Slide 26: First Patients Treated
fell testa First Patients Treated! “"We have already delivered the first Ethos therapy treatment and our clinical staff Sep 9-12 were impressed by the capabilities and the ability to deliver this advanced treatment ina typical timeslot.” Patients treated “Ethos therapy will enable our physicians Avg

Slide 27: Adaptive Intelligence Consortium
Adaptive Intelligence Consortium of clinical\outcome benefi Goal: Accelerate ption and provide ev { y UZ PennMedicine | LEUVEN Radiation Oncology \ CANCER INSTEFUTE, = UCSD > He The James sterling & Q) momeseartmnmm CANCE Rage 1 WKF aR ; seu cuceRHOSeTAL “= ICON: tb © KINDA! UNIVERSITY ‘ PennState H

Slide 28: CTSI
varian CTSI Andrew Shogan Senior Vice President, CTSI

Slide 29: CTSI oncology platform
CTSI oncology platform Diagnostic, therapeutic and clinical support delivery capabilities in any global market Founded in 2008 by a group of oncologists from UPMC Oncology Clinical Diagnostic Services Delivery Services » Facilitate improved siz, AMERICAN accessibility to and affordability iia CTS 1

Slide 30: CTSI strategy accelerating global access to quality care
CTSI strategy accelerating global access to quality care Early global examples may UMC Vija | x | wa HEALTH M SsysTEM ledtech Clinical services Clinical services support and training Clinical services. support China professional services Ao G | Nacheaith Technology and Technology clinical partnershi

Slide 31: Clinical services engagement: UMC Health System
Clinical services engagement SYSTEM Illustrative opportunity: UMC Health System a * Large public health system and primary teaching hospital for Texas Tech University * Increasing levels of support over the past two years » Numerous achievements that support expansion of UMC’s oncology program bs $2

Slide 32: Varian + CTSI: Solutions for unmet patient & provider needs
Varian + CTSI: Solutions for unmet patient & provider needs Feedback loop of data will drive cost- and time-effective innovation » Brings Varian closer to the ; : Enables enhanced tech- patient and provider to Drives developmentofnew i : gain data driven clinical tech-enabled services enabled servic

Slide 33: Noona
varian Noona Corey Zankowski, PhD Senior Vice President, Oncology Software Solutions

Slide 34: Noona overview
Noona overview nC number of Acquired Noona Healthcare October 2018, developer of a cloud-based, mobile service to capture cancer patient-reported outcomes (PROs) Designed to capture structured PRO data Includes proactive patient symptoms management Superior UVJUX (modem & engaging app) May improve c

Slide 35: Commercial model combines SaaS and life sciences
Commercial model combines Saa& and life sciences sponsored studies to drive revenue for Noona Private practice networks Selected group of IDNs Selected group of AMCs New Mexico Cancer Center Private practice networks ARIA MO premium clients Tennessee Oncology TOP 15 Pharma Immunotherapies and new or

Slide 36: Interventional Oncology
varian Interventional Oncology Kolleen Kennedy President, Proton Solutions and Chief Growth Officer

Slide 37: Acquisitions provide leading position
Acquisitions provide leading position Expand Varian’s addressable market to include interventional oncology 7 Interventional Oncology WW Market Value ($M)* Why enter interventional aan arket Value (SM oncology market? she $1,050 $1,000 The first and only provider with an end- to-end suite of integra

Slide 38: Overview of interventional oncology treatment modalities
Overview of interventional oncology treatment modalities Acquisitions provide assets in thermal ablation and microsphere embolization Use of concentrated thermal energy to either heat/burn or Tiny particles block tumor's access to blood, causing freeze tumor tumor to “starve” + Loe Embolization (¥90

Slide 39: Varian's vision for an interventional oncology platform
Varian’s vision for an interventional oncology platform Hardware and software solutions spanning multiple modalities eee Thm Tm Tmo Tm aca ees Ablation Embolization ny @ Alicgn Oncozene/ Build robust Embozene acoaystemot Bion resorbabie Tandem’ interventional ge! foam part oncology planning Embozene

Slide 40: Building a comprehensive and differentiated platform offering
Building a comprehensive and differentiated platform offering Next steps in building Varian’s interventional oncology ecosystem Build global commercial team including direct sales and distribution network Expand cryotherapy and microwave product sales into new markets worldwide Priorities for the bu

Slide 41: Proton Solutions
varian Proton Solutions Kolleen Kennedy President, Proton Solutions and Chief Growth Officer

Slide 42: ProBeam 360 Proton Therapy System
ProBeam® 380" Proton Uherapy System ration Proto Now available in multi-room configuration 4 ‘Smallest multi-room system available for sale Smaller Smaller Reduction in Volume Footprint vault cost Profan 360° 2 ganty) ForivEsroR Use Reductions dependent on configuration Legacy 2 oanty System

Slide 43: RapidPlan PT
"7 @ RapidPlan” PT The first application of Machine Learning for proton planning varian.

Slide 44: RapidPlan PT
RapidPlan™ PT Rapidly expanding model-building proton community Mon CGranepharyngioma Model by CCHNG \@ Liver HOC Medal by Varin ‘ = ‘ase of Stl Mode by PSI (Gyrecologe Mode by Glasgow

Slide 45: Flash Therapy
varian Flash Therapy Dee Khuntia, MD Senior Vice President and Chief Medical Officer

Slide 46: FLASH Publication Timeline
FLASH Publication Timeline Investments in FLASH research activities started in 2015 and with our FlashForward™ Consortium announcement last year, the fervor has only grown FLASH Publications 2014-Present he 2015 2016 2018 2019 2014 2017 3 8 FLASHIFLASH related publications by midyear 2019 © romnwest

Slide 47: Ultra-high dose external beam therapy delivered in less than 1 second
Ultra-high dose external beam therapy delivered in less than 1 second, in 1 to 3 treatments FLASH Range | 40 Gy/sec — 120 Gy/sec 9! ProBeam Research Mode 720,000 cGy Permin FLASH ee TrueBeam |) 2,4000cy linac | 400 Gy oeGy ‘100000 200000 300000 400000 500000 720000 For weston use ony varian FLASH th

Slide 48: Varian FlashForward Program
Varian FlashForward™ Program Stanford University Medical Center Electron FLASH Toxicity and Tumor Control Studies 2014 2015 2016 University of Maryland Cincinnati Proton Thorapy Center First Proton FLASH Tumor Controt Study 2018 2019 First Proton FLASH. Toxlety Study 2017 Varian granted 5 U.S. paten

Slide 49: ProBeam Proton Therapy Sites 2019
ProBeam® Proton Therapy Sites 2019 @ Operational centers @ Centers Under Development > FlashForward Consortium Member varian

Slide 50: Multifaceted FLASH Strategy
Multifaceted FLASH Strategy Mechanism of Action Safe Treatments Long-term Research Vv Vv Vv varian FLASH therapy is under preclinical research. Its not available for clinical use and there fs no guarantee of future commercialization

Slide 51: Flash reduces differential gene expression
Flash reduces differential gene expression normally observed with radiation therapy Down-regulated genes Normal Lung Tissue 639 13 24 hr 40 yDOwN,

Slide 52: Conventional Proton
Conventional Proton Tumor Core Control! Conventional Tumor Core varian

Slide 53: Publications 2019 (FLASH) — National & International Meetings
Publications 2019 (FLASH) — National & International Meetings + AACR: Meeting March 29 ~ April 3, 2019 > Girdhani, Parry et al - FLASH: a novel paradigm changing tumor irradiation platform that enhances therapeutic ratio by reducing normal tissue toxicity and activating immune pathways + PTCOG: Meet

Slide 54: Q&A and Closing Remarks
varian Q&A and Closing Remarks Dow Wilson President and Chief Executive Officer

Slide 55: Varian to host 2019 Investor Day meeting in NYC
Varian to host 2019 Investor Day meeting in NYC Share our vision for a world without fear of cancer... + Time: 8:00am to 1:00pm ET on November 15, 2019 + Location: The Plaza Hotel, Fifth Avenue at Central Park South, New York, NY 10019 * Objective: Varian’s management team will outline growth initia

Slide 56: Varian leadership update — year later
Varian leadership update — 1 year later Kolleen Kennedy Chief Growth Officer President, Proton Solutions Strengthening Proton business — three new orders Flash program Interventional oncology Acquisition integration Cardiac radio-ablation Chris Toth President, Oncology Systems * Continued strong mom

Slide 57: Varian leadership team
an leadership team Vari

Slide 58: In summary, we are...
In summary, we are... ri Continuing to strengthen leadership in radiation oncology J Leveraging artificial intelligence, machine learning and 4 cloud solutions to drive efficiency and effectiveness (f-}) Growing emerging businesses and technologies | Growing Varian Value Add through operational and
Source: SEC EDGAR · 8-K filed Sep 16, 2019
More decks from Varian Medical Systems Inc
Q1 FY2021 Earnings Presentation29 slides · Jan 26, 2021
Q4 FY2020 Earnings Presentation30 slides · Oct 27, 2020
Merger or Acquisition (August 2020)33 slides · Aug 4, 2020
Merger or Acquisition (August 2020)18 slides · Aug 3, 2020
Q3 FY2020 Earnings Presentation36 slides · Aug 3, 2020
Q2 FY2020 Earnings Presentation36 slides · May 4, 2020